Documentary record · EMERGENCY NORMATIVE GUIDANCE

WHO: Ervebo protection against Bundibugyo virus is unestablished; off-label use recommended only within research protocols

GUIDANCE ISSUED

Event date

September 1, 2026

Jurisdiction

Global

Issuing body

WHO

Action type

EMERGENCY NORMATIVE GUIDANCE

Lifecycle state

GUIDANCE ISSUED

Verification date

1 September 2026

Normative WHO guidance. It binds no member state directly and authorises nothing; it states what WHO recommends and, more importantly here, what the evidence does not establish.

What this establishes

  • WHO has evaluated potential use of licensed Ervebo during Bundibugyo virus disease outbreaks.
  • WHO’s conclusion is that available evidence is insufficient to establish clinically meaningful protection in humans against Bundibugyo virus.
  • WHO recommends any BDBV use of Ervebo only within a research protocol.
  • WHO recommends generating efficacy evidence through a ring randomised controlled trial, continuing proven outbreak-control measures, communicating uncertainty, and accelerating BDBV-specific vaccines and therapeutics.

What this does not establish

  • That Ervebo is effective against Bundibugyo virus. WHO says the opposite: efficacy is unestablished, not established.
  • That no vaccine exists. Ervebo is a licensed Ebola vaccine; the licensure does not extend to demonstrated BDBV protection.
  • That off-label use is prohibited. WHO recommends confining it to research protocols — a recommendation, not a prohibition.
  • Any change in the PHEIC state or in national border measures.

Why it matters

The distinction this guidance turns on is one the site now carries as a data field rather than a sentence: a product can be licensed while its efficacy against a particular pathogen within the same family is unestablished. Writing "no vaccine exists" is wrong, and writing "a vaccine is available" is worse. The accurate formulation is that there remains no vaccine with established licensed efficacy specifically against Bundibugyo virus disease, and that WHO, having examined off-label use of a licensed Ebola vaccine, found the human evidence insufficient and recommends research-protocol use only.

The open question

When a licensed product may be the only candidate available during an outbreak, what evidentiary threshold should govern its deployment — and who decides whether a ring trial is feasible in the middle of an epidemic?

Primary source

Register: data/events.json · record id who-bundibugyo-ervebo-guidance-2026-09-01.